Continuous glucose monitors like DexCom’s G6 and G7 and Abbott’s FreeStyle Libre 2 and 3 have blurred the line between medical devices and consumer goods. Packaged alongside sleek smartphone apps and marketed directly to patients, CGMs have changed the game for diabetics, payers and doctors looking to recommend therapies.
A similar, albeit slower, transformation is taking place amongst insulin pumps. Medtech Insight spoke to Elizabeth Gasser, chief strategy officer...